logo
Plus   Neg
Share
Email

Aurinia Pharmaceuticals Inc. (AUPH) Is Climbing On Study Results

Aurinia Pharmaceuticals Inc. (AUPH) announced after the bell Wednesday that its Phase 2b study in lupus nephritis met the complete and partial remission endpoints. The stock is now up 1.59 on 1.9 million shares.

Aurinia Pharmaceuticals climbed for the bulk of the morning Wednesday and closed up by 0.15 at $3.71.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT